Search Results

The Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees who are poised to redefine what is possible in cancer research.

BostonGene and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, announced today the launch of a collaboration aimed at uncovering molecular mechanisms underlying IO treatment response and treatment-related toxicity in advanced cancer patients and discovering actionable blood-based biomarkers.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer.

Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors.

Parker Health, a biotechnology company, names Philip McDonald, MD as the company’s first Chief Medical Officer.

Sebela Pharmaceuticals, a US pharmaceutical company with a market leading position in gastroenterology and a focus on innovation in women’s health, today announced the appointment of Victor Parker to the position of Chief Commercial Officer.

Guardant Health, Inc. and the Parker Institute for Cancer Immunotherapy (PICI) today announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer.